DATA GRAPHICS | Product Development
mRNA vaccines still lead the COVID-19 pack: Data Byte
Sinovac’s Phase III data ranks vaccine lowest in protection rate
January 13, 2021 2:31 AM UTC
mRNA vaccines were the first to be authorized, and pivotal data show them to still be the most effective as a sixth COVID-19 vaccine reads out.
Brazil’s Butantan Institute, which led Phase III testing of CoronaVac, said Tuesday that the inactivated SARS-CoV-2 vaccine from China’s Sinovac Biotech Ltd. (NASDAQ:SVA) had an overall efficacy of 50.3% in Phase III testing...